Related Experiment Videos
Neomycin inhibits angiogenin-induced angiogenesis
1Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA. guofu_hu@harvard.edu
Summary
Neomycin, an antibiotic, inhibits angiogenin-induced angiogenesis by blocking nuclear translocation. This discovery suggests neomycin as a potential therapeutic agent for anti-angiogenesis therapies.
Area of Science:
- Molecular Biology
- Cell Biology
- Pharmacology
Background:
- Angiogenesis is crucial for tumor growth and is mediated by factors like angiogenin.
- Angiogenin's nuclear translocation is essential for its angiogenic activity.
- Developing inhibitors of angiogenin is a key strategy for anti-cancer therapy.
Purpose of the Study:
- To investigate the mechanism of angiogenin action.
- To identify potential inhibitors of angiogenin-induced angiogenesis.
- To explore neomycin's role as an angiogenesis inhibitor.
Main Methods:
- Studied the effect of neomycin on human angiogenin nuclear translocation in endothelial cells.
- Assessed the impact of neomycin on endothelial cell proliferation.
- Evaluated neomycin's efficacy in inhibiting angiogenesis using the chicken chorioallantoic membrane model.
- Tested other aminoglycoside antibiotics for similar effects.
Main Results:
- Neomycin inhibits human angiogenin nuclear translocation, dependent on phospholipase C inhibition.
- Neomycin dose-dependently inhibits angiogenin-induced endothelial cell proliferation without affecting basal proliferation or viability.
- Other aminoglycosides like gentamicin do not inhibit angiogenin-induced proliferation.
- Neomycin effectively inhibits angiogenesis in the chicken chorioallantoic membrane model.
Conclusions:
- Neomycin acts as an angiogenesis inhibitor by interfering with angiogenin's nuclear translocation.
- Neomycin's mechanism involves phospholipase C inhibition.
- Neomycin and its analogs show promise for developing novel anti-angiogenesis therapies.